Finance

Lists
Why is LYEL down 8.57%?
Dive Deeper
LYEL:NASDAQ
Lyell Immunopharma Inc
$14.30
-8.57%
(-1.34) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LYEL...
Open
$15.54
High
$15.76
Low
$14.20
Mkt. cap
456.64M
Avg. vol.
216.48K
Volume
236.66K
52-wk high
$45.00
52-wk low
$7.32
EPS
-$11.74
Beta
-0.04
Shares outstanding
24.59M
No. of employees
161
Open
$15.54
High
$15.76
Low
$14.20
Mkt. cap
456.64M
Avg. vol.
216.48K
Volume
236.66K
52-wk high
$45.00
52-wk low
$7.32
EPS
-$11.74
Beta
-0.04
Shares outstanding
24.59M
No. of employees
161
News stories
From web sources and news partners
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Websitelyell.com
Analyst ratings
Based on 5 analysts giving stock ratings to LYEL in the past 3 months
Buy
Buy
4
Hold
0
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for LYEL in the last 3 months.
Highest
Current $14.30
$44.00 (+207.69%)
Average
$34.80 (+143.36%)
Lowest
$12.00 (-16.08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$39.00
+172.7%
11/13/2026
Stephen Willey
Stifel Nicolaus
Buy
Reiterated
$35.00
+144.8%
11/05/2026
Jason Zemansky
Bank of America Securities
Sell
Maintained
$12.00
-16.1%
11/04/2026
Yuan Zhi
B. Riley Securities
Buy
Maintained
$44.00
+207.7%
09/24/2026
Gil Blum
Needham
Buy
Maintained
$44.00
+207.7%
09/11/2026
Jack Allen
Robert W. Baird
Buy
Initiated
$49.00
+242.7%
05/01/2026
Reni Benjamin
Citizens JMP
Buy
Initiated
$34.00
+137.8%
03/09/2026
Last report
Nov 4, 2026
Fiscal period
Q3 2026
-$1.69 / -$1.88
+10.15%beat
Revenue / Est. (USD)
3.00K / 2.60K
+15.38%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
6.00K
2.00K
4.00K
3.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
52.20M
36.60M
39.52M
40.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.62M
9.56M
9.58M
9.30M
Operating expense
61.48M
44.26M
47.34M
48.30M
Total operating expenses
61.48M
44.26M
47.34M
48.30M
Operating income
-61.48M
-44.26M
-47.34M
-48.30M
Other non operating income
-17.46M
17.91M
398.00K
861.00K
EBT including unusual items
-140.72M
-24.15M
-44.76M
-45.53M
EBT excluding unusual items
-76.26M
-24.15M
-44.76M
-45.53M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-1.33M
-1.90M
-1.76M
-1.90M
Net income
-140.72M
-24.15M
-44.76M
-45.53M
Net profit margin
-2,345,383.33%
-1,207,650.00%
-1,118,875.00%
-1,517,633.33%
Earnings per share
-
-
-1.74
-1.69
Interest and investment income
2.68M
2.19M
2.18M
1.90M
Interest expense
-
-
-
-
Net interest expenses
2.68M
2.19M
2.18M
1.90M
Depreciation and amortization charges
-
-
-
-
EBITDA
-59.08M
-41.93M
-45.12M
-46.24M
Gain or loss from assets sale
-166.00K
-
117.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps